Translational Research Program (TRP) Chair: Adam P. Dicker, MD, PhD Brain Arnab Chakravarti, MD Breast Wendy Woodward, MD, PhD Steven Chimura, MD, PhD.

Slides:



Advertisements
Similar presentations
1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.
Advertisements

AACI 2008 State Funding for Cancer Centers Shelton Earp, MD.
Strategic Goal #5: T1 Translational Research Brian Athey University of Michigan.
Retreat Topics iPSC Opportunities in NIAMS Diseases Science Management Forum: Leveraging and Strategic Funding Collaborations Atopic Dermatitis Advancing.
Role of the Statistician and the Bioinformatics Scientist in Cancer Clinical Trials Larry Rubinstein, PhD Biometric Research Branch, NCI International.
PLENARY SESSION Fall Group Meeting Miami, FL November 13, 2010.
Disclosure I, Peter T. Katzmarzyk, PhD, FACSM, have no relationships with commercial interests to disclose. A commercial interest is any entity producing,
Kathryn E. Weaver, PhD, MPH co-Principal Investigator, WF NCORP RB Presentation to Translational Cancer Genomics Working Group December 16 th, 2014.
Statistical Issues in Incorporating and Testing Biomarkers in Phase III Clinical Trials FDA/Industry Workshop; September 29, 2006 Daniel Sargent, PhD Sumithra.
Michael Birrer, PI, Director, Gynecologic Medical Oncology, MGH Lari Wenzel, Co-PI, Prof. of Medicine, University of California, Irvine
Merging Scientific and Advocate Communities: The Transdisciplinary Research Model in the BCERC Kami J. Silk, Ph.D. Department of Communication Michigan.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
Todays Clinical Trials. Tomorrow’s Cures. Robert L. Comis, MD 1 National Coalition for Cancer Research “Cancer 101” Congressional Briefing 09/10/14.
Signature Research and Academic Collaborations Status Report to RHEDC February 15, 2007.
Hartford Hospital Helen & Harry Gray Cancer Center, Hartford, Connecticut.
Norris Cotton Cancer Center Global Update CTOP RETREAT May 2014.
Stress Regulation of Tumor Biology Robert T. Croyle, PhD Director Division of Cancer Control and Population Sciences Concept Presentation NCI Board of.
CTOS: A Herman Suit Legacy Michael A. Simon, MD The University of Chicago.
ACRIN Research Associates Educational Session Radiation Therapy Oncology Group Research Associates Committee Joyce Neading, RHIT, CTR Program Director,
Critical Path Opportunities for Biologics Products Jesse L. Goodman, M.D. M.P.H. Director Kathryn M. Carbone, M.D. Associate Director for Research Center.
Comprehensive Thoracic Oncology Program: COG Update CTOP Research Retreat David Nalepinski Director, Oncology Service Line & Business Operations May 23,
Leveraging Patient Engagement & the Role of Advocacy.
NIH Roadmap for Medical Research and Common Fund Update on Recent Changes Dinah Singer, Ph.D. Director, Division of Cancer Biology June 18, 2008.
Grants. The mission of the Quantitative Imaging Network (QIN) is to improve the role of quantitative imaging for clinical decision making in oncology.
USF Health Leadership Judy L. Genshaft, PhD President, University of South Florida Stephen K. Klasko, MD, MBA, Sr. Vice President, USF Health Dean, USF.
NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.
1 Targeted Strategies to Improve Physician and Patient Access to Cancer Clinical Research An Overview of Coalition Programs and Services Ruth Lambersky.
University of Michigan Medical School Academy for Educational Excellence and Scholarship Monthly Seminar – June 23, Academy updates, year in review:
Developing Relationships: Cooperative Group Networking Developing Relationships: Cooperative Group Networking Kandie Dempsey, MS, RN, OCN, CCRP Delaware.
BIOMEDICAL IMAGING PROGRAM NATIONAL CANCER INSTITUTE.
ACRIN Fall Meeting 2008 Mitchell Schnall MD, PhD Professor of Radiology University of Pennsylvania ACRIN Network Chair State of ACRIN : 10 years of investment.
SARC Career Development Award Program Richard Gorlick, MD Lee Helman, MD.
Extramural Program and Funding Opportunities: NCI David H. Harpole, Jr., M.D. Professor of Surgery Vice Chief of Surgical Sciences Department of Surgery.
CCR Clinical Research Priorities Clinical research is an essential part of the CCR research program Translational (collaborative) Interaction between basic.
State of ACRIN : Extending our reach
How can we work together? Partnering with Industry: An Investigator’s Perspective Robert L. Coleman, MD M. D. Anderson Cancer Center.
The Cancer Systems Biology Consortium (CSBC)
Gynecologic Oncology Group Gynecologic Oncology Group (GOG) Sharon Stockman, C-CRC The University of Iowa Hospitals Iowa City, IA Chair, GOG Data Management.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.
Other Intramural Training Opportunities at NCI Scientific DisciplinesProgram Population-based research, environmental & genetic determinants of cancer.
The Use of Predictive Biomarkers in Clinical Trial Design Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute
James D. Bearden, III, MD, FACP Principle Investigator Gibbs Cancer Center, Spartanburg, SC Gibbs Cancer Center Our NCCCP Journey 1.
National Center for Research Resources G. Iris Obrams, M.D., M.P.H., Ph.D. NCRR Update 5 August 2006.
The Wisconsin Network for Health Research (WiNHR): Overview. An Infrastructure for Conducting Multi-Site Clinical Research across the State of Wisconsin.
Robert H. Wiltrout Director, CCR Director’s Address.
Role of the Drug Project Team in Formulating the Initial Development Plan of NCI-IND agents Jeff Moscow, MD IDB, CTEP.
Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.
NIH and the Clinical Research Enterprise Third Annual Medical Research Summit March 6, 2003 Mary S. McCabe National Institute of Health.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Full Proposal for the German Cancer Aid Priority Program 'Translational Oncology' (2st call) 2015 Lead Applicants: Prof. Dr. med. Magnus von Knebel Doeberitz.
UK Clinical Sarcoma Research. Changes in UK Appointment of Cancer Tsar Use of NICE to evaluate care pathways and technology/drugs Minimum datasets established.
OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.
NCI Phase III Treatment Portfolio in Prostate Cancer: Opportunities for Embedding Surrogate Endpoint Questions Alison Martin, M.D. Cancer Therapy Evaluation.
NCI Division of Cancer Prevention Ongoing Activities at Frederick Facilities Presented By: Lori Minasian, M.D. Robert Shoemaker, Ph.D. October 1, 2015.
11 Radiation Therapy Oncology Group Clinical Trials Administration Sharon Hartson Stine, Director Group Administrator.
Current Protocols of the Radiation Therapy Oncology Group Montreal, Quebec Nov. 12, 2004.
Where we REALLY want To Be: Where we were : Organizational Strategy.
ACOSOG Sarcoma Committee Chair: Peter W.T. Pisters, MD Vice Chairs: Edward Cheng, MD (Orthopedic Oncology) Robert Maki, MD, PhD (Medical Oncology) Brian.
National Cancer Institute
Cancer Center: A Pathway to Collaborative Research and NCI Designation Mark Reeves, MD, PhD, Cancer Center Director 2016 Research Symposium, 10/21/16.
Innovation for Healthier Americans
Yale SPORE in Skin Cancer
Sarah Leary, MD MS CBTTC 5/25/2016
RTOG 0126 A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer Bijoy.
Evaluation of biologically equivalent dose escalation, clinical outcome, and toxicity in prostate cancer radiotherapy: A meta-analysis of 12,000 patients.
NRG Oncology Biospecimen Bank Report NRG Semiannual meeting
Clinical Trial Development: NRG Processes and NCI Requirements
Clinical Trial Development: NRG Processes and NCI Requirements
Presentation transcript:

Translational Research Program (TRP) Chair: Adam P. Dicker, MD, PhD Brain Arnab Chakravarti, MD Breast Wendy Woodward, MD, PhD Steven Chimura, MD, PhD Gastrointestinal Chandan Guha, MD Sunil Krishnan, MD Genitourinary Allan Pollack, MD, PhD Head & Neck Christine H. Chung, MD Gynecology Joanne Weidhaas, MD, PhD Molecular Signatures Christine H. Chung, MD Normal Tissue Effects Deborah Citrin, MD Barry Rosenstein, PhD Ulrich Rodeck, MD, PhD Bioinformatics Joseph O. Deasy, PhD Soren Bentzen, PhD Publications Arnab Chakravarti, MD Sarcoma William Kraybill, MD David Kirsh, MD, PhD Dina Lev, MD, PhD Tissue Bank Fred Waldman, MD, PhD Trans-Canada Robert G. Bristow, MD, PhD Matthew B. Parliament, MD Lung Quynh Le, MD, PhD Protons Jason Efstathiou, DSc, MD EORTC Eric Deutch, MD

Radiation Therapy Oncology Group RTOG Strengths Unique Mission Outstanding Scientific Leadership Transformational Research Growing Accrual Translational Research with Funding Pivotal Phase III Trials Leader in New Technologies

Radiation Therapy Oncology Group Strengths Outstanding Databases Growing Membership Base Outstanding Staff in HQ and Biostat Unique Link with ATC and RPC Non-Federal Sources of Funding Unique Relationship with ACR Core Group of Member Institutions Canadian-European-Asian Link

4 4 Goals of the TRP Leverage the rapid evolution of translational research to support RTOG’s mission –Representation in TRP Surgery, Pathology, Medical Oncology, Radiation Oncology, Basic Science, Translational Science, Statistics, Patient Advocacy –New liaisons and subcommittees ATIC Breast Molecular Signatures Outcomes/Quality of Life, Normal Tissue Protons Bioinformatics Trans-Canada

5 5 Operational Roles of TRP Operational Roles of TRP Recruit scientistsRecruit scientists Identify promising resources/technologiesIdentify promising resources/technologies Group member education and feedbackGroup member education and feedback Seed grant funding for novel ideasSeed grant funding for novel ideas

6 Process for Evaluating Seed Grant Proposals Biospecimen Resource RTOG Statistics Disease Site Liaisons External Advisory Committee Feedback to Applicant TRP Chair RTOG HQ RTOG Steering Committee RFA and application,

7 7 Scientific Roles of TRP Scientific Roles of TRP Hypothesis generation and validationHypothesis generation and validation Incorporation of TRP endpoints into trialsIncorporation of TRP endpoints into trials Trial analysis and factors modelingTrial analysis and factors modeling

8 8 Themes of TRP Identify signatures of resistant local diseaseIdentify signatures of resistant local disease Identify markers for patterns of failureIdentify markers for patterns of failure Identify and improve normal tissue risk prediction modelsIdentify and improve normal tissue risk prediction models

Required Infrastructure Tumor and Tissue Bank (LDS, Utah) Biostatistical Link with Clinical Data Translational Researchers across the globe Peer-Reviewed Funding (RO1, R29, GO) RT Delivery Databases (St Louis) Outcomes Databases (Philadelphia) Translational Research

Radiation Therapy Oncology Group RTOG Biospecimen Resource Fred Waldman, M.D.,Ph.D. Jeff Simko, M.D., Ph.D. Richard Jordan, Ph.D., DDS Ken Aldape, M.D., Ph.D. Sandy DeVries, M.S.

Radiation Therapy Oncology Group Inventory as of January, 2010 Brain3159 cases/ 35 trials GU10586 cases / 32 trials GI3032 cases / 18 trials Gyn283 cases / 7 trials Head/Neck4220 cases / 17 trials Lung448 cases / 13 trials Sarcoma213 cases / 8 trials TMAs27 TMAs Total21,977 cases / 132 trials (2264 cases w buffy coat, 2156 plasma, 2438 serum)

12 Biomarkers/biological factors Dosimetric factors Outcomes = physics and biology Outcome variation Statistical models of combined factors Joe Deasy, Wash Univ.

13 Global RTOG Strategy Candidate gene polymorphisms and RT/Chemo toxicity Opportunities for survivorship studies

14 Hypothesis Patients with identical DVHs/field size will have different toxicities that are governed by gene polymorphisms that influence signal amplification from DNA damaging agents.

15 Research Links Links to National Research CommunityLinks to National Research Community –NCI Steering Committee Involvement –SPORE/PO1 Collaborations –SWOG Interactions –AACR –ASTRO (RTOG Foundation) –RFA on RTOG website Links to International Research CommunityLinks to International Research Community –EORTC and NCIC Representation